Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Next Previous
Trial Profile

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimatoprost (Primary) ; Timolol
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ARTEMIS; ARTEMIS 1
  • Sponsors Allergan

Most Recent Events

  • 01 Jan 2023 Results from NCT02247804 and NCT02250651; evaluating the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that lowers intraocular pressure without the need for daily eye drops, published in the Journal of Ocular Pharmacology and Therapeutics
  • 28 May 2022 Results of a pooled analysis of data from 2 phase III studies and one phase I/II study (NCT02247804, NCT02250651, and NCT01157364) assessed the single administration of intracameral Bimatoprost implant 10 µg in patients with Open-Angle Glaucoma or Ocular Hypertension, published in the Ophthalmology and Therapy
  • 27 Apr 2021 According to an AbbVie media release, data from the new analyses of the Phase 3 ARTEMIS studies examining the duration of intraocular pressure (IOP) lowering and biodegradation kinetics of DURYSTA, will be presented at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top